{"id":296227,"date":"2025-05-14T00:00:00","date_gmt":"2025-05-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0019-2023-biopharma-axial-spondyloarthritis-unmet-need-unmet-need-nonradiographic-axial\/"},"modified":"2026-03-31T10:26:15","modified_gmt":"2026-03-31T10:26:15","slug":"unneim0019-2025-biopharma-axial-spondyloarthritis-unmet-need-unmet-need-nonradiographic-axial-spondyloarthritis-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0019-2025-biopharma-axial-spondyloarthritis-unmet-need-unmet-need-nonradiographic-axial-spondyloarthritis-us-eu\/","title":{"rendered":"Axial Spondyloarthritis &#8211; Unmet Need &#8211; Unmet Need &#8211; Nonradiographic Axial Spondyloarthritis (US\/EU)"},"content":{"rendered":"<p>TNF-alpha inhibitors, such as AbbVie\u2019s Humira, Amgen\u2019s Enbrel, Johnson &#038; Johnson Innovative Medicine\u2019s Simponi, and UCB\u2019s Cimzia, are approved for the treatment of nonradiographic axial spondyloarthritis (nr-AxSpA) in Europe. While Cimzia is the only FDA-approved TNF-alpha inhibitor for nr-AxSpA in the United States, the other drugs in the class are increasingly used off-label. Alongside TNF-\u03b1 inhibitors, IL-17 inhibitors (like Novartis\u2019s Cosentyx, Eli Lilly\u2019s Taltz, the recently approved Bimzelx [UCB]) are also used to treat nr-AxSpA in both regions. Another interesting option for nr-AxSpA is AbbVie\u2019s oral JAK inhibitor, Rinvoq. Xeljanz may be used off-label for the indication, but evidence supporting its use remains limited. In this report, we examine areas of unmet need in the treatment of nr-AxSpA, including short-term efficacy, improvement in patient-reported quality of life, mechanism of action, safety and tolerability, delivery, and price. With quantitative insight into U.S. and European rheumatologists\u2019 assessment of the unmet need in nr-AxSpA, we discuss the commercial opportunities for this difficult-to-diagnose indication and how emerging therapies can capitalize on these opportunities.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the treatment drivers and goals for <abbr data-abbreviation-entity=\"6651\" title=\"nonradiographic axial spondyloarthritis\">nr-AxSpA<\/abbr>?<\/li>\n<li>Which drug attributes are key influences, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for <abbr data-abbreviation-entity=\"6651\" title=\"nonradiographic axial spondyloarthritis\">nr-AxSpA<\/abbr>?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in <abbr data-abbreviation-entity=\"6651\" title=\"nonradiographic axial spondyloarthritis\">nr-AxSpA<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new <abbr data-abbreviation-entity=\"6651\" title=\"nonradiographic axial spondyloarthritis\">nr-AxSpA<\/abbr> drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<div>\n<p>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW35284845 BCX0 round-bullets\">\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the TPP Simulator.<\/li>\n<\/ul>\n<p><strong>Key feature<\/strong><\/p>\n<p>Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.<\/p>\n<\/div>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31 European rheumatologists fielded in January 2025<\/p>\n<p><strong>Key drugs:<\/strong> Humira, Cimzia, Cosentyx, Taltz, Rinvoq, Xeljanz, <abbr title=\"nonsteroidal anti-inflammatory drug\">NSAID<\/abbr>s<\/p>\n","protected":false},"template":"","class_list":["post-296227","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-therapy-areas-rheumatology","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296227\/revisions"}],"predecessor-version":[{"id":575789,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/296227\/revisions\/575789"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=296227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}